Integra LifeSciences (NASDAQ:IART) Rating Lowered to Hold at StockNews.com

Integra LifeSciences (NASDAQ:IART) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Tuesday.

Other equities research analysts also recently issued research reports about the company. JMP Securities lowered their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research report on Wednesday, April 3rd. Finally, Truist Financial lowered their price target on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Trading Up 0.0 %

Shares of IART stock opened at $29.18 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a 52-week low of $27.18 and a 52-week high of $55.46. The company has a market capitalization of $2.29 billion, a PE ratio of 35.16, a price-to-earnings-growth ratio of 0.88 and a beta of 1.12. The business’s fifty day moving average is $34.70 and its 200 day moving average is $38.64.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same quarter last year, the business posted $0.94 EPS. The company’s quarterly revenue was down .3% on a year-over-year basis. On average, equities research analysts anticipate that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Arizona State Retirement System increased its holdings in shares of Integra LifeSciences by 1.3% in the third quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock worth $802,000 after buying an additional 279 shares during the period. Cardinal Capital Management increased its holdings in shares of Integra LifeSciences by 1.6% in the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock worth $962,000 after buying an additional 347 shares during the period. Hexagon Capital Partners LLC grew its stake in shares of Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 370 shares during the last quarter. Inspire Investing LLC grew its stake in shares of Integra LifeSciences by 5.1% in the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock worth $306,000 after purchasing an additional 392 shares during the last quarter. Finally, State of Michigan Retirement System grew its stake in shares of Integra LifeSciences by 2.5% in the first quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock worth $592,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.